Stocks
IGM Biosciences Financial Statements (IGMS) |
||||||||||
| IGM Biosciencessmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 26.03.2020 | 30.03.2021 | 29.03.2022 | 30.03.2023 | 07.03.2024 | 08.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.000 | 0.000 | 1.07 | 2.13 | 2.11 | |||
| Operating Income, bln rub | -44.5 | -83.3 | -165.3 | -228.0 | -263.5 | -253.9 | ||||
| EBITDA, bln rub | ? | -44.5 | -83.3 | -165.3 | -228.0 | -255.2 | -249.6 | |||
| Net profit, bln rub | ? | -42.5 | -80.3 | -160.7 | -214.2 | -246.4 | -236.9 | |||
| OCF, bln rub | ? | -45.1 | -67.3 | -124.3 | -5.85 | -192.2 | -183.7 | |||
| CAPEX, bln rub | ? | 2.34 | 17.5 | 13.2 | 10.2 | 12.4 | 10.9 | |||
| FCF, bln rub | ? | -47.5 | -84.8 | -137.6 | -16.1 | -204.6 | -194.6 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 44.5 | 83.3 | 165.3 | 229.0 | 257.3 | 253.9 | ||||
| Cost of production, bln rub | 2.33 | 3.58 | 7.72 | 10.6 | 8.28 | 10.1 | ||||
| R&D, bln rub | 35.3 | 65.0 | 127.0 | 179.3 | 207.2 | 206.3 | ||||
| Interest expenses, bln rub | 0.000 | 0.000 | 0.000 | 6.85 | 0.000 | 3.98 | ||||
| Assets, bln rub | 261.4 | 408.6 | 298.1 | 513.5 | 423.4 | 376.1 | ||||
| Net Assets, bln rub | ? | -107.2 | -188.6 | -353.7 | -574.8 | 203.2 | 161.3 | |||
| Debt, bln rub | 14.7 | 12.2 | 28.8 | 41.2 | 40.5 | 40.9 | ||||
| Cash, bln rub | 236.6 | 366.3 | 229.5 | 427.2 | 338.3 | 294.1 | ||||
| Net debt, bln rub | -221.9 | -354.0 | -200.8 | -386.0 | -297.8 | -253.2 | ||||
| Ordinary share price, rub | 38.2 | 88.3 | 29.3 | 17.0 | 8.31 | 4.74 | ||||
| Number of ordinary shares, mln | 9.00 | 30.7 | 33.5 | 41.5 | 52.3 | 60.1 | ||||
| Market cap, bln rub | 343 | 2 715 | 982 | 707 | 435 | 285 | ||||
| EV, bln rub | ? | 121 | 2 361 | 781 | 321 | 137 | 32 | |||
| Book value, bln rub | -107 | -189 | -354 | -575 | 203 | 161 | ||||
| EPS, rub | ? | -4.73 | -2.61 | -4.80 | -5.16 | -4.71 | -3.94 | |||
| FCF/share, rub | -5.28 | -2.76 | -4.11 | -0.39 | -3.91 | -3.24 | ||||
| BV/share, rub | -11.9 | -6.13 | -10.6 | -13.8 | 3.89 | 2.68 | ||||
| EBITDA margin, % | ? | -21 324% | -11 980% | -11 857% | ||||||
| Net margin, % | ? | -20 042% | -11 569% | -11 255% | ||||||
| FCF yield, % | ? | -13.8% | -3.12% | -14.0% | -2.27% | -47.1% | -68.3% | |||
| ROE, % | ? | 39.7% | 42.6% | 45.4% | 37.3% | -121.2% | -146.9% | |||
| ROA, % | ? | -16.3% | -19.7% | -53.9% | -41.7% | -58.2% | -63.0% | |||
| P/E | ? | -8.07 | -33.8 | -6.11 | -3.30 | -1.76 | -1.20 | |||
| P/FCF | -7.23 | -32.0 | -7.14 | -44.0 | -2.12 | -1.46 | ||||
| P/S | ? | 661.1 | 204.1 | 135.4 | ||||||
| P/BV | ? | -3.20 | -14.4 | -2.78 | -1.23 | 2.14 | 1.77 | |||
| EV/EBITDA | ? | -2.73 | -28.3 | -4.73 | -1.41 | -0.54 | -0.13 | |||
| Debt/EBITDA | 4.99 | 4.25 | 1.21 | 1.69 | 1.17 | 1.01 | ||||
| R&D/CAPEX, % | 1 509% | 371.6% | 959.1% | 1 757% | 1 674% | 1 887% | ||||
| CAPEX/Revenue, % | 954.7% | 581.3% | 519.1% | |||||||
| IGM Biosciences shareholders | ||||||||||
